Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this postmarketing surveillance is to obtain further information about the tolerability and efficacy of Berodual® metered-dose inhaler in the treatment of chronic obstructive respiratory tract disease under conditions of daily practice

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Fenoterol; Fenoterol, ipratropium drug combination; Ipratropium

Criteria

Inclusion Criteria:

• Patients of either sex over 40 years with the symptoms of a chronic obstructive airways disease

• Only patients which have not been treated with Berodual® within the last year should be included

Exclusion Criteria:

• Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Berodual® metered-dose inhaler